Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
With FDA clearance of its IND, the company has begun studying the drug's dosing and preliminary activity in previously treated, ALK-positive, advanced NSCLC.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
